Abstract 7299: CS2009: A first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFA with potential to be a next-generation backbone therapy with combined checkpoint inhibition and anti-angiogenesis
Chuan Wang(Qilu Hospital of Shandong University), Jianxin Yang(Ascepion Pharmaceuticals (China)), Xueqin Dai(Ascepion Pharmaceuticals (China)), Yi Sun(Ascepion Pharmaceuticals (China)), Yilin Huo(Ascepion Pharmaceuticals (China)), Y. S. La(Ascepion Pharmaceuticals (China)), Ning Zhang(Ascepion Pharmaceuticals (China)), Xuelian Liu(Ascepion Pharmaceuticals (China)), Yongli Yang(Southwest Forestry University), Xinling Zhang(Qingdao University), Yongwang Li(Shenzhen Third People’s Hospital), Fei Ma(Ascepion Pharmaceuticals (China)), Jingyu Sun(Shanghai East Hospital)
Cited by 4
Related Papers
Design and Mechanisms of Asymmetric Supercapacitors
|Chemical Reviews|2018|3.6k
Crafting Mussel‐Inspired Metal Nanoparticle‐Decorated Ultrathin Graphitic Carbon Nitride for the Degradation of Chemical Pollutants and Production of Chemical Resources
|Advanced Materials|2019|422
Bridging the Gap between Reality and Ideal in Chemical Vapor Deposition Growth of Graphene
|Chemical Reviews|2018|396
Towards super-clean graphene
|Nature Communications|2019|217